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ABSTRACT 
The aim of present research work was to formulate and evaluate nanosuspension of fenofibrate which is categorized as BCS class II agent. With 
an intention to increase solubility and dissolution rate of fenofibrate nanosuspension were prepared by high pressure homogenization method, 
a top down technique. Using poloxamer 188 and Tween 80 as a stabilizer. Formulation scheme was developed by Box Behnken Desig n. 
Formulation factor which affect the particle size includes Concentration of surfactant and processing parameters includes Homogenization 
pressure and Homogenization cycles. In this study practically water insoluble fenofibrate was nanosized and surfactant was added for their 
stabilizing effect. In vitro dissolution study showed that the increase in the release rate of fenofibrate from nanoparticles as compared to pure 
drug. Scanning electron microscopy study showed that the spherical morphology of nanoparticles. Particle size distribution, zeta potential, 
crystal form of formulated nanosuspension were studied by using particle size analyzer, and X-ray powder diffraction, Ex-vivo study for 
calculating absorption rate. The result showed that the drug dissolution rate in nanosuspension formulation is depends upon the crystal form, 
solubility, procedure involved, and stabilizer used. 
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INTRODUCTION  
Solubility is the most important parameter for a drug to 
show good bioavailability and hence therapeutic effect1, 2. 
More than 40% of new drug entities are poorly water soluble 
which frequently create problems in formulating them into 
conventional dosage forms and result in poor 
bioavailability3. 
Fenofibrate is a antihyperlipidemic belonging to BCS class II, 
it is practically insoluble in water (0.3µg/ml at 37 ) and has 
high lipophilicity (logP 5.3), thus it is evident that the rate 
limiting step for the absorption of fenofibrate from 
gastrointestinal tract is the dissolution4, 5. The solubility / 
dissolution of drugs can be improved using various 
conventional techniques such as micronization, precipitation 
technology, Salt formation and others like liposome, 
microemulsion, solid dispersion, and inclusion complexation 
with cyclodextrin. Various approaches have been reported 
for solubility improvement of fenofibrate6, 7, 8. 
Nanotechnology can be used to solve the problems 
associated with these conventional approaches for solubility 
and bioavailability enhancement. Nanoparticulates offer an 
efficient method as reduction in particle radius coupled with 
high energy surfaces contribute to improve saturation 
solubility9, 10. 
The nanoparticulates of fenofibrate have been reported by 
methods such as melt emulsification and precipitation11, 12. 
 Present work describes the formulation and optimization of 
nanosuspension of fenofibrate by using a high pressure 
homogenizer. The formulation and process parameters 
surfactant concentration, homogenization pressure and 
homogenization cycle are optimized   using Box Behnken 
Design to obtain lowest particle size13. The nanoparticles 
were evaluated for DSC, PXRD and SEM analysis. These 
nanoparticles were incorporated into the tablet formulation 
and subjected to invitro dissolution and exvivo absorption 
studies.   
MATERIALS AND METHODS 
Materials 
Fenofibrate was obtained from Medley pharmaceutical Ltd, 
Research centre, poloxamer 188 (Lutrol F68) was given from 
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Vishal chem, Mumbai:400 002, Tween 80 was  purchased 
from SD Fine-chem. Pvt. Ltd. Mumbai, SLS (Sodium Lauryl 
Sulfate )was obtained from LOBA chemicals Mumbai LTD. 
and all other chemicals were obtained from local sources and 
were of analytical grade. 
Standard Calibration Curve of Fenofibrate 
 Standard calibration curve of fenofibrate was developed by 
suitably diluting methanolic stock solution of fenfibrate in 
1% SLS solution in distilled water to obtain concentrations 
between 5 to 30μg/ml. The absorbance of resulting solutions 
was measured at 290 nm using double beam UV-Visible 
Spectrophotometer against 1% SLS solution as blank14. 
Determination of drug solubility in the various 
surfactants 
The drug was added in excess amount into 5mL of each 
surfactant (Tween 80, Tween 60, Tween 20, Span 80, 
PEG400, PEG 600, and Transcutol) in separate vials and 
stirred for 24 h. at room temperature on Orbital Shaker. The 
equilibrated samples were removed from stirrer and 
centrifuged at 3000 rpm for 15min to remove the excess 
drug. The supernatant was filtered through a 0.45μm 
membrane filter. The concentration of drug in supernatant 
was measured by UV spectrophotometer after appropriate 
dilution with methanol at 290 nm the drug solubility 
(mg/mL) was measured spectrophotometrically15. 
Formulation and optimization of nanosuspension 
Nanosuspension was prepared by High pressure 
homogenization technique. Initially coarse suspensions of 
fenofibrate were formulated by adding solution of 
fenofibrate in acetone to the solution of surfactant 
combination (Poloxamer 188 and Tween 80) in different 
ratios in distilled water. The mixture was then stirred on 
mechanical stirrer at 5000 rpm for 30 min. The formulated 
coarse suspension were subjected to high pressure 
homogenization using  (1000 Bar Homogenization  Pressure 
and 9 Homogenization  Cycles) Using GEA-Nirosoavi panda 
plus 2000. 
Experimental Design 
A Box Behnken Design of 13 experimental runs was used to 
evaluate three variables at 3 levels viz. Concentration of 
Tween 80 (0.2%, 0.4%, 0.6%), and the concentration of 
poloxamer 188 was kept constant. And varying the 
concentration of tween 80. Homogenization pressure (400, 
700, 1000 Bar) and Homogenization cycles (6, 9, 12) in order 
to determine their effect on two responses particle size, Zeta 
potential and their interaction therein. The layout of the 
experimental design is shown in Table 1. 
 
Table 1: Translation of experimental conditions into physical units for preparation of Fenofibrate nanosuspension. 
Sr. No. Factor 1(A):  Concentration tween 
80 (%) 
Factor 2 (B): Homogenization 
pressure (Bar) 
Factor 3 (C): Homogenization 
cycles (Unit) 
-1 0.2 400 6 
0 0.4 700 9 
+1 0.6 1000 12 
 
Evaluation of Nanosuspension: 
 Particle size and PDI analysis 
The particle size analysis of the prepared Fenofibrate 
nanosuspension performed using Malvern Zetasizer ZS 90 
(Malvern Instruments, Worcestershire, UK), utilizing laser 
diffraction with beam length 2.40 mm, range lens of 300 RF 
mm, and at 14.4% obscuration. The sample was diluted in 
distilled water prior to the analysis. The mean diameter and 
the poly dispersity index of each batch were recorded. And 
each sample was analyzed in triplicate. 
Zeta potential: 
The measurement of zeta potential was carried out using the 
additional electrode of Malvern Zetasizer that was used for 
particle size and PDI analysis. A sample of nanosuspension 
was diluted with distilled water and subjected into 
disposable sizing cuvette for measurement at temperature of 
25°C with setting of dispersant RI at 1.33 and dielectric 
constant of dispersant at 78.5 in triplicates. 
Lyophilization of nanosuspension 
The optimized nanosuspension batch was rapidly frozen at -
86℃ freezer and freeze dried using 2.5 Freezone, Labconco 
equipments Ltd at a vacuum degree of 200 pas, -30℃ for 48 
h to yield a dry sample. 
 Differential Scanning Calorimetry (DSC): 
DSC was performed on Mettler-Toledo DSC 823* (Columbus) 
instrument and an empty standard aluminium pan were 
used as reference. DSC scans were recorded at heating rate 
of 10◦C/ min in temperature range 30-300◦C, DSC 
measurements were carried out on lyophilized fenofibrate 
nanosuspension. 
X-ray diffraction (XRD) study: 
X-ray scattering measurements were carried out with an X-
ray diffractometer (PW 3710, Philips Ltd). A Cu Ka radiation 
source was used, and the scanning rate (2h/min) was 5℃ 
per min. X ray diffraction measurements were carried out on 
unprocessed fenofibrate powder and fenofibrate 
nanosuspension. 
Saturation Solubility Studies: 
Nanosuspensions equivalent to 50 mg of Fenofibrate were 
taken and separately introduced into 25mL stoppered 
conical flask containing 10mL distilled water. The flasks 
were sealed and placed in rotary shaker for 24hrs at 37°C 
and equilibrated for 2days. The samples were collected after 
the specified time interval and it was filtered and diluted 
appropriately. The diluted samples were analyzed using UV 
spectrophotometer at 290 nm. 
Scanning Electron Microscopy 
SEM was used to verify the uniformity of particle shape and 
size. The sample was smeared on a small piece of adhesive 
carbon tape which is fixed on a brass stub. The sample, then 
s 
ubjected to gold coating using sputtering unit for 10sec at 
10mA of current. The gold coated sample placed in chamber 
of SEM and secondary electron/back scattered electron 
images were recorded. 
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Formulation of tablet containing Fenofibrate 
nanoparticles  
Fenofibrate nanoparticles, lactose, MCC (Microcrystalline 
cellulose PH 101), were blended and the powder was 
moistened using Povidone k30 solution in water was used as 
a binder. (Table 2) dough was passed through sieve no 10 
dried in oven at 50℃. The dried mass was mixed with cross 
povidone, magnesium stearate and SLS (Sodium Lauryl 
Sulphate).  Compressed using 6 mm punch using B tooling 
on Rimek tablet machine (Make Karnavati). 
Table 2: Formula for tablet containing nanoparticles of 
fenofibrate 
Ingredients Quantity (mg) 
Fenofibrate nanoparticles 
Equivalent to 45 mg fenofibrate 
47  
Lactose 32 
MCC(PH 101) 10 
Cross povidone 5 
SLS 2 
PVP K 30 3 
Magnesium stearte 1 
Total 100 mg 
 
In vitro dissolution study:  
  In vitro dissolution study was carried out using USP 
dissolution apparatus II. 
The rotation speed of the paddles was set to 100 rpm. About 
900 mL of 1.0% SDS 
at 37 ± 0.5°C was used as the dissolution medium. At 
predetermined time intervals 5 mL samples were 
withdrawn, filtered through 0.22 µm membrane 
immediately, and 5 mL blank dissolution medium was added 
for replenishing of the dissolution medium, respectively. 
The amount of dissolved drug was determined at 290 nm 
using a UV spectrophotometer. 
Ex-vivo permeation studies using everted rat intestine 
To understand the absorption mechanism of 
nanosuspension, everted gut sac studies using rat intestinal 
segments were performed. Intestine was washed carefully 
with Krebs ringer solution and different segments of small 
intestine were identified. A length of 8–10 cm was rapidly 
removed and gently everted over a glass rod. The everted 
intestine was then slipped off the glass rod and placed in a 
flat dish containing Krebs–Henseleit bicarbonate (KHB) 
buffer oxygenated with O2/CO2 (95%/5%) at 370C. The in 
vitro absorption system consisted of USP dissolution 
apparatus II operated at 100 rpm containing 1% SDS (1000 
ml) as dissolution medium maintained at 37±0.5℃. Modified 
perfusion apparatus holding isolated everted intestine 
segment was placed in dissolution vessel.  
In this system, drug dissolution from formulation and 
permeation across everted intestine occurred 
simultaneously. 
The marketed tablet and tablet containing fenofibrate 
nanoparticles was transferred in separate dissolution 
vessels. The aliquotes were collected at predetermined time 
intervals of 5, 10, 15, 30, 45, 60, 90 min and the equal 
volumes of dissolution and serosal fluids were replaced.  The 
samples were analyzed spectrophotometrically at 290 nm17. 
RESULTS AND DISCUSION 
Standard Calibration Curve of fenofibrate: 
The absorption maxima of fenofibrate are reported at 290 
nm.13 A linear relationship between the concentration and 
absorbance of fenofibrate were established over the 
examined concentration range (5-30 μg/mL). Calibration 
curve of fenofibrate was established (Fig 1).  The equation of 
line was y = 0.021x + 0.009 and R² = 0.998.  
 
Figure 1: Calibration Curve of fenofibrate in 1% SLS. 
 Solubility Determination: The solubility of fenofibrate in 
various surfactants is Given in (Fig 2). 
 
Figure 2: Solubility data of Fenofibrate in various 
surfactants
 
Formulation and optimization of nanoparticles: 
Table 3: Particle size of nanoparticles at various surfactant Concentrations : 
Sr No Surfactant system Surfactant Ratio (%) Particle size(nm) 
1 Poloxamer 188: Tween 80 0.2:0.2 750 
2 Poloxamer 188: Tween 80 0.2:0.4 420 
3 Poloxamer 188: Tween 80 0.2:0.6 300 
 
Tween 80 was selected due to high solubility of fenofibrate 
(50.10 mg/mL) (Fig 2).  While poloxamer 188 was selected 
as the hydrophobic poly propylene oxide chains can drive 
the polymer to be adsorbed on the surface of the drug 
particles, while the hydrophilic PEO chains surround the 
drug particles and provide a steric hindrance against 
aggregation. This is evident from particle size in Table 3. 
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Experimental Design 
Table 4: Experimental run and responses for optimization of Fenofibrate nanosuspension formula using Box-Behnken 
design.(*n=3 i.e. average of three readings) 
  Factor 1 Factor 2 Factor 3 Response 1 Response 2 
Std Run A:Concentration of 
Tween 80 (%) 
B:Homogenization 
Pressure 
Bar 
C:Homogenization 
Cycles 
Unit 
Particle Size 
Nm 
Zeta 
potential 
mV 
1 1 0.2 400 9 584 -18.2 
9 2 0.4 400 6 452 -21.3 
13 3 0.4 700 9 353 -19.2 
2 4 06 400 9 338 -24.6 
12 5 0.4 1000 12 402 -21.0 
4 6 0.6 1000 9 298 -31.2 
8 7 0.6 700 12 312 -28.0 
6 8 0.6 700 6 332 -29.2 
11 9 0.4 400 12 464 -17.1 
10 10 0.4 1000 6 442 -18.2 
5 11 0.2 700 6 612 -16.0 
7 12 0.2 700 12 592 -16.2 
3 13 0.2 1000 9 584 -17.0 
 
 
 Determination of Particle Size: 
The particle size of prepared nanoparticles ranged between 
290-630 nm Table 4. It is evident from the findings that 
increase in the Stabilizer concentration decreases the 
particle size. From this we could conclude that the prepared 
suspension is in nano size. Polydispersity index (PDI) is the 
measure of size distribution and varies from 0.0 to 1.0. The 
closer the PDI value to zero, the more homogenous is the 
nanosuspension, the PDI for prepared nanosuspensions of 
trial runs were between 0.102-0.302, hence indicating good 
homogeneity.  
 Determination of Zeta potential: 
Zeta potential analysis is a technique for determining the 
surface charge of nanoparticles in solution (colloids). The 
electric potential at the boundary of the double layer is 
known as the zeta potential of the particles and is taken as a 
measure for stability of nanosuspension. Poloxamer 188 and 
Tween 80 are non-ionic surfactant is used as a stabilizer 
which provides steric stabilization so negative zeta potential 
is attributed to nanocrystal.  The range of zeta potential was 
found to be -16 to -31.2 mV. 
Optimization Data Analysis: 
The statistical model generated for particle size is 
represented by equation 1 
                                      
                                     
                …………Equation 1, 
Concentration of surfactant (A) is having greater effect on 
particle size whereas homogenization pressure (B) and 
homogenization cycles (C) which is having significantly less 
effect on the particle size. The interaction between A & B i.e. 
Concentration of Tween 80 and homogenization pressure 
was more dominant in reducing the particle size compared 
with that of AC and BC. (Fig 4, 5). 
The interaction term AC i.e. the particle size was seen to be 
decreasing with the increase in the concentration of 
surfactant but the influence of homogenization cycle on 
particle size was not so dominant. As tween 80 and 
poloxamer forms a protective coat around the drug particles 
thus preventing the aggregation of the particles upon size 
reduction. Increasing homogenization pressure reduces the 
particle size, which is due to homogenizing valve under high 
density fluid dynamic energy conditions. Similar effects were 
shown in (Fig 3, 4, and 5). 
 
 
Figure 3: Response surface plot showing influence of 
Concentration of Tween 80 and Homogenization 
pressure on Particle size. 
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Figure 4: Response surface plot showing influence of 
Concentration of Tween 80 and Homogenization Cycles 
on Particle size. 
 
Figure 5: Response surface plot showing influence of 
Homogenization pressure and Homogenization cycles 
on Particle size. 
 
Equation for Zeta potential: 
                                    
                                      
                 ……………. Equation 2, 
The model indicates that as the concentration of Surfactant 
goes on increasing the Zeta potential .Tween 80 and 
poloxamer 188 is a non-ionic surfactant which is used as a 
stabilizer, which provides steric stabilization so the Negative 
zeta potential attributed to the drug nanocrystal. The 
interaction term BC and AC did not have dominant effect on 
Zeta potential as these contributing merely to reduce the 
particle size. (Fig 7 and 8). 
 
Figure 6: Response surface plot showing influence of 
Concentration of Tween 80 and Homogenization 
pressure on Zeta potential. 
 
Figure 7: Response surface plot showing influence of 
Homogenization pressure and Homogenization Cycles 
on Zeta potential. 
 
Figure 8: Response surface plot showing influence of 
Concentration of Tween 80 and Homogenization Cycles 
on Zeta potential. 
The formulations prepared as per the experimental design 
were evaluated and the analysis of experimental results was 
done by using Stat-Ease Design Expert. The ANOVA, P-value 
and Model F-value for particle size and Zeta potential were 
obtained Table 5. 
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Table 5: ANOVA output of the Box-Behnken Design for Optimization of Fenofibrate nanosuspension 
Sr. No. Outcomes Particle size Zeta potential 
1 Models Quadratic Quadratic 
2 R2    VALUE 0.9985 0.9846 
3 F – VALUE 221.47 21.31 
4 P – VALUE 0.0005 0.0144 
5 ADEQUATE PRECISION 40.0139 13.3992 
 
F value for both models was found to be high which indicated 
that the models were significant. P value less than 0.05 
indicated that the model terms were significant. Adequate 
precision indicates signal to noise ratio, its value higher than 
4 indicates minimum noise. Higher R2 value indicated good 
agreement between formulation variables and response 
parameters. Thus both models can be used to predict the 
values of the response parameters at selected values of 
formulation variables within the design space. 
 
Validation of the Response Surface Methodology (RSM): 
Thus, the formulation batch giving minimum particle size 
and maximum Zeta potential was chosen as the optimized 
batch based on desirability function (1). Thus, the optimized 
batch consisted of concentration of tween 80 (0.6%) 
Homogenization pressure (1000 Bar) and (9) 
homogenization cycles. To evaluate the findings of the RSM, 
verification run was carried out and no significant difference 
was found between the theoretical and the actual values of 
particle size and Zeta potential is given in Table 6. Thus the 
model is seen to have good prognostic ability. 
 
Table 6: Check Points for optimization, actual, predicted value and % error (n=3, Mean± SD) 
Formulation 
Code 
Composition of 
optimized formulation 
Response Predicted 
Value 
Actual Value % Error 
X1 X2 X3 
Optimized 
batch 
0.6% 1000 
Bar 
9 Y1 294.37 nm 298 nm 1.21 
Y2 -31.16 mV -31.2 mV 0.769 
 
 
Evaluation of Nanosuspension 
Differential Scanning Calorimetry (DSC) 
 
Figure 9: A. DSC Thermogram of Unprocessed 
Fenofibrate ,  B. DSC Thermogram of Lyophilized 
fenofibrate nanosuspension. 
DSC thermogram of fenofibrate and lyophilized fenofibrate 
nanosuspension shown in (Fig 9).  The sharp endothermic 
peak ascribed to the melting point was obtained for the 
formulation. However slightly lower melting observed for 
formulation than that of unprocessed fenofibrate is might be 
due to smaller particle size and subsequent amorphisation17. 
 
 
 
 
 
X-ray diffraction (XRD) study 
 
Figure 10: XRD data of a) Unprocessed fenofibrate 
powder b) Lyophilized fenofibrate nanosuspension. 
X- ray diffraction pattern of unprocessed fenofibrate powder 
and lyophilized fenofibrate nanosuspension are shown in 
(Fig 10). It was found that no crystalline changes were found 
in the lyophilized fenofibrate nanosuspension, because their 
powder X-ray diffraction pattern was consistent with the 
pattern of raw crystals and spherical crystals. However the 
differences in the relative intensities of their peaks might be 
attributed to the differences in the crystallinity of the 
sample. 
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Saturation Solubility Studies: 
Table 7: Saturation solubility study 
Media Solubility at 37±1℃ 
(mg/ml) [n=3, mean ±S.D] 
Unprocessed 
Fenofibrate 
Nanosuspension 
PH 6.8 2.2±0.12 9.12±0.23 
PH 7.4 3.4±0.16 11.34±0.32 
Distilled 
water 
1.7±0.11 9.52±0.15 
 
Saturation solubility for unprocessed fenofibrate and 
lyophilized nanosuspension is given in Table 7. 
Approximately 4 times increase in saturation solubility of 
lyophilized nanosuspension was observed than that of 
unprocessed drug. 
The explanation for increase in saturation solubility can be 
given with Ostwald‑Freundlich’s equation which is 
described as follows. 
        (
   
    
) 
Where S is the saturation solubility,  
S∞ is the solubility of the solid consisting of infinitely large 
particles,  
 γ is the interfacial tension of substance,  
M is the compound molecular weight, 
 R is the gas constant,  
T is the absolute temperature,  
Þ is the density of the solid and  
r is the radius.  
This equation is significant below 1 µm. This makes 
nanosizing is more efficient than 
Micronization. Another possible explanation for the 
increased saturation solubility is the creation of high-energy 
surfaces when disrupting the more or less ideal drug 
microcrystal’s to nanoparticles. Lyophobic surfaces from the 
inside of the crystal are exposed to the aqueous dispersion 
medium during nanosizing. According to Ostwal-
Freundlich’s equation, S is dependent on the interfacial 
tension γ and subsequently on the interfacial energy G 
(G=γA). Differences in interfacial energy have a profound 
effect on the saturation solubilities of polymorphic forms of 
the drug; the same explanation might be valid for the 
nanosuspension (high energy form = polymorph II = higher 
S) compared to microparticulate suspensions (low energy 
form = stable polymorph I = lower S 
 
 
Scanning Electron Microscopy: 
 
Figure 11: SEM photomicrograph of Fenofibrate nanosuspension 
 
Morphology of precipitated drug particles in the suspension 
after air drying followed by oven-drying is shown in (Fig 11). 
The drug particles precipitated with the Poloxamer188 as 
stabilizer were oval in shape and the size ranges from 290 
nm. The particles were discrete and uniform in size and 
there was no sign of agglomerations.  
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In-Vitro Drug release and Ex vivo Permeation study: 17 
 
Figure 12: In vitro drug release from fenofibrate nanopartiulates, tablet containing nanoparticulates and conventional 
tablet. 
Ex-vivo permeation studies using everted rat intestine: 
 
Figure 13: Ex-Vivo Permeation Study 
 
Table 8: Comparison of In-vitro % cumulative release against Ex-vivo % permeation 
Time(min) invitro % cumulative Release Exvivo % cumulative Permeated 
Marketed Tablet Fenofibrate nanoparticles 
incorporate in tablet 
Marketed Tablet Fenofibrate 
nanoparticles 
incorporate in tablet 
0 0 0 0 0 
5 15.23 58.3 1.27 5.95 
10 28.2 64.2 3.82 8.91 
15 42.1 73.1 5.95 17.4 
30 48.21 79.9 9.78 25.5 
45 52.36 84.2 12.76 35.74 
60 64.3 94.7 14.89 48.51 
75 - - 17.02 57.02 
90 - - 18.72 66.38 
 
Marketed fenofibrate tablet shows 64.3% release within 60 
min. While Freeze dried fenofibrate nanoparticles shows 
96.2% release within 60 min. And these freeze dried 
nanoparticles incorporate into a tablet dosage form that 
shows the 94.7% release within 60 min.  Marketed 
fenofibrate tablet showed 18.72% absorption with 
absorption rate 0.122 while Fenofibrate nanoparticle tablet 
showed 66.38% absorption with absorption rate of 0.234. 
Increase in the absorption rate might be due to the increase 
in solubility and dissolution rate. Increase in dissolution rate 
results into increased concentration gradient which cause 
increase in flux. 
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CONCLUSION 
High pressure homogenization method can be successfully 
employed to produce a stable fenofibrate nanosuspension. 
By this method showed significant improvement in aqueous 
solubility as well as dissolution characteristics which may 
improve its oral bioavailability.  
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